Vaccine Market - By Technology & Types, Trend Analysis By Various Classes - Live / Attenuated, Subunit, Toxoid, Conjugate, DNA, Recombinant Vector, Synthetic, Dentritic Vaccines And By Indications - Infectious Diseases, Cancer, Allergy, Diabetes, Cardiova

News provided by

Aug 13, 2013, 06:47 ET

NEW YORK, Aug. 13, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Vaccine Market - By Technology & Types, Trend Analysis By Various Classes - Live / Attenuated, Subunit, Toxoid, Conjugate, DNA, Recombinant Vector, Synthetic, Dentritic Vaccines And By Indications - Infectious Diseases, Cancer, Allergy, Diabetes, Cardiova
http://www.reportlinker.com/p01595393/Vaccine-Market---By-Technology--Types-Trend-Analysis-By-Various-Classes---Live-/-Attenuated-Subunit-Toxoid-Conjugate-DNA-Recombinant-Vector-Synthetic-Dentritic-Vaccines-And-By-Indications---Infectious-Diseases-Cancer-Allergy-Diabetes-Cardiova.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

The vaccine market is an established segment and is widely accepted as an indispensable division of the healthcare industry. It is poised to grow rapidly by addressing the following: emerging infectious agents, various types of cancer, allergies, cardiovascular diseases, diabetes, smoke cessation, and neurodegenerative disorders. The global vaccine market is estimated at $32.05 billion in 2013 and is expected to reach $84.44 billion by 2022.

In general, the vaccine market is largely perceived negatively as a low-profit venture owing to the domination of top five companies, namely, Sanofi (France), Glaxo Smithkline (U.K.), Merck (U.S.), Pfizer (U.S.), and Novartis (Switzerland). Furthermore, a strong patent portfolio and the need for large investments towards vaccine development have limited the scope of entry for new companies.

The vaccine market is analyzed both in terms of qualitative (technological) and quantitative (revenue) perspectives. The technological analysis includes a discussion on different classes of vaccines, vaccine adjuvants, and commercially available products. The market revenue analysis includes market segmentation and the expected market position by 2022, with the projected growth rate.

The vaccine market is classified by technology class, types, end users, disease indication, and geography. The details on the emerging approaches to vaccine development such as reverse vaccinology, personalized vaccinomics, and systems vaccinomics are discussed. Furthermore, key research centers, with their critical areas of research in the vaccine space, have been provided.

An overview of regulations across various geographical regions has been covered. The complete value chain of the vaccine market is schematically represented and the significance of each stakeholder has been briefed.

Apart from the technological and market analysis, the investor climate has been assessed by tracking the complete investor network and collecting data on funds/grants and investments made towards vaccine development. Insights on current and future technological investment trends have also been discussed.

A large number of potential therapeutic and preventive vaccine candidates addressing various diseases which are in the pipeline are listed with their current status in clinical trials.
The adoption and developmental potential of the vaccine technology market has been discussed on a geographic basis, namely, North America, Europe, Asia, and the Rest of the World, by taking select countries that are poised to have a greater market value during the forecast period.

In brief, this research report provides:

A detailed description of the global technology developments and evolving trends in the vaccine field with key prominence on research innovations, collaborative efforts, and investments for vaccines.
A close view on the therapeutic vaccines for various diseases by providing details and status of current vaccines in the pipeline.
An impact analysis of the major drivers and restraints influencing the adoption and growth of the vaccine market during the period of 2013 to 2022.
Porters five forces analysis and GAP analysis.
The global market forecast for 2013 - 2022, including demand side analysis and strategic recommendations for technology/product developers.
Competitive landscape tracking industry activities such as mergers, acquisitions, partnerships, collaborations, and strategic agreements within the vaccine market. Intellectual property strength analysis based on the number of patents filed by the top five players within the vaccine market that gives an insight into prominent activities and global leaders of the industry.

Scope of the Report

This research report categorizes the global vaccine market into technology class, types, end users, disease indication, and geography. Each segment is further broken down by geography, with exhaustive revenue analysis for 2012 and 2013, as well as the forecast up to 2022.

Global Vaccine Market, by Technology Class

Live
Toxoid
Conjugate
Sub-Unit
Recombinant Vector Vaccines
DNA Vaccines
Synthetic Vaccines
Dentritic Vaccines

Global Vaccine Market, by Types

Preventive
Therapeutic

Global Vaccine Market, by End Users

Pediatric
Adult

Global Vaccine Market, by Disease Indication

Infectious Diseases
Cancer
Allergies
Others

Global Vaccine Market, by Geography

North America
Europe
Asia-Pacific
Rest of the World (RoW)

1 INTRODUCTION 19

1,1 Key Take-Aways
1,2 Report Scope
1,3 Report Segmentation
1,4 Research Methodology
1,5 Key Data Points From Secondary and Primary Sources
1,6 Logical Assumptions in this Study Based on Reliable Sources

2 EXECUTIVE SUMMARY 26

3 TECHNOLOGY SNAPSHOT 31

3,1 Technology – Introduction
3,2 Technology – Evolution
3,3 Technology Segmentation
3,4 Technology Trends – by Class
3.4.2 Adjuvants
3,5 Key Vaccine Products in the Market
3,6 Technology Roadmap

4 VACCINE RESEARCH PORTFOLIO 42

4,1 Global Research Portfolio – Research and Development Network
4,2 Emerging Approaches to Vaccine Developments
4,3 Key Research Centres

5 VALUE CHAIN ANALYSIS 47

5,1 Overview
5,2 Cold Chain Management
5,3 Key Stakeholders
5,4 Gap Analysis
5,5 Porters Five Force Analysis

6 MARKET LANDSCAPE 57

6,1 Global Vaccine Technologies Market, Global Forecasts (2013 – 2022)
6.1.1 Global Vaccine Technologies Market, By Geography, 2012 – 2022
6.1.2 Vaccine Technologies Market Segmentation
6.1.3 Market Dynamics
6.1.3.1 Drivers
6.1.3.2 Restraints
6.1.3.3 Opportunities, Threats and Challenges
6,2 Global Vaccine Technologies Market, By End-User, 2012-2022
6.2.1 Global Vaccine Technologies Market Share, By End-User, 2012 – 2022
6.2.2 Paedriatic Vaccine Market, By Geography
6.2.3 Global Paedriatic Vaccine Market Share, By Geography
6.2.4 Global Adult Vaccine Market, By Geography
6.2.5 Global Adult Vaccine Market Share, By Geography
6,3 Global Vaccine Technologies Market, By Type, 2012-2022
6.3.1 Global Vaccine Technologies Market Share, By Type, 2012-2022
6.3.2 Global Preventive Vaccine Market, By Geography, 2012 – 2022
6.3.3 Global Preventive Vaccine Market Share, By Geography, 2012-2022
6.3.4 Global Therapeutic Vaccine Market, By Geography, 2012 – 2022
6.3.5 Global Therapeutic Vaccine Market Share, By Geography, 2012 – 2022
6,4 Global Vaccine Technologies Market, By Class, 2012 – 2022
6.4.1 Global Vaccine Technologies Market Share, By Class, 2012-2022
6.4.2 Live/Attenuated Vaccine Market, By Geography
6.4.2.1 Live/ Attenuated Vaccine Market Share, By Geography
6.4.3 Toxoid Vaccine Market, By Geography
6.4.3.1 Toxoid Vaccine Market Share, By Geography
6.4.4 Conjugate Vaccine Market, By Geography
6.4.4.1 Conjugate Vaccine Market Share, By Geography
6.4.5 Sub-unit Vaccine Market, By Geography
6.4.6 Recombinant Vector Vaccine Market, By Geography, 2012 – 2022
6.4.6.1 Recombinant Vector Vaccine Market Share, By Geography, 2012 – 2022
6.4.7 DNA Vaccine Market, By Geography, 2012 – 2022
6.4.8 Synthetic Vaccine Market, By Geography, 2012 – 2022
6.4.8.1 Synthetic Vaccine Market Share, By Geography, 2012 – 2022
6.4.9 Dentritic Vaccine Market, By Geography, 2012 – 2022
6.4.9.1 Dentritic Vaccine Market Share, By Geography, 2012 – 2022
6,5 Vaccine Market, By Disease Indication (2012 - 2022)
6.5.1 Infectious Disease Vaccine Market, By Geography
6.5.2 Cancer Vaccine Market, By Geography
6.5.3 Allergy Vaccine Market, By Geography
6.5.4 Others Vaccine Market, By Geography, 2012 – 2022
6.5.5 Others Potential Market, By Geography, 2016 – 2022

7 TECHNOLOGY ADOPTION 110

7,1 Factors that Drive Adoption of Vaccine Technologies (Demand and Supply Side Analysis)
7,2 North America – U.S. & Canada
7,3 Europe – U.K, Germany, France, Italy
7,4 Asia – China, India
7,5 RoW – Australia & Africa

8 INVESTMENT ANALYSIS 122

8,1 Investor Network
8,2 Investment Funding Analysis
8,3 Top Funding Organizations

9 COMPETITIVE LANDSCAPE 126

9,1 Competitive Landscape Analysis – Overview
9,2 Key Acquisitions/Partnerships/Agreements/Collaborations (2012 – 2013)
9,3 Vaccine Candidates in Pipeline – Allergy
9,4 Vaccine Candidates in Pipeline – Cancer
9,5 Vaccine Candidates in Pipeline – Infectious Diseases
9,6 Vaccine Candidates in Pipeline – Others

10 REGULATORY LANDSCAPE 135

10,1 Regulatory Landscape – Overview
10,2 Regulations – Geographic

11 PATENT ANALYSIS 140

11,1 PATENT ANALYSIS – OVERVIEW
11,2 PATENT ANALYSIS BY COMPANY

12 ANALYST RECOMMENDATIONS 143

12,1 Introduction
12,2 Technology Management Strategies

13 COMPANY PROFILES 146

13,1 NOVARTIS AG
13,2 GLAXO SMITHKLINE PLC
13,3 MERCK & CO., INC.
13,4 SANOFI
13,5 PFIZER, INC.
13,6 ANTIGEN EXPRESS, INC.
13,7 ADURO BIOTECH
13,8 GENTICEL
13,9 BIONDVAX PHARMACEUTICALS LTD
13,10 IMMUNE TARGETING SYSTEMS (ITS)
13,11 PROKARIUM
13,12 IMMUNOBIOLOGY LTD
13,13 LIQUIDIA TECHNOLOGIES
13,14 ALPHAVAX
13,15 BAVARIAN NORDIC

14 APPENDIX 177

Inter-country Comparison of Mortality for Selected Cause of Death

List of Tables

1 VACCINE TECHNOLOGIES MARKET, BY GEOGRAPHY, 2012 – 2022 ($BILLION) 59
2 GLOBAL VACCINE TECHNOLOGIES MARKET, BY END-USER, 2012 – 2022 ($BILLION) 69
3 PAEDRIATIC VACCINE MARKET, BY GEOGRAPHY, 2012 – 2022 ($BILLION) 71
4 ADULT VACCINE MARKET, BY GEOGRAPHY, 2012 – 2022 ($BILLION) 73
5 GLOBAL VACCINE TECHNOLOGIES MARKET, BY TYPE, 2012 – 2022 ($BILLION) 75
6 GLOBAL PREVENTIVE VACCINE MARKET, BY GEOGRAPHY, 2012 – 2022 ( $BILLION) 77
7 THERAPEUTIC VACCINE MARKET, BY GEOGRAPHY, 2012 – 2022 ($BILLION) 79
8 GLOBAL VACCINE TECHNOLOGIES MARKET, BY TECHNOLOGY CLASS, 2012 – 2022 ($BILLION) 81
9 GLOBAL LIVE VACCINE MARKET, BY GEOGRAPHY, 2012-2022 ($BILLION) 84
10 TOXOID VACCINE MARKET, BY GEOGRAPHY, 2012 – 2022 ($BILLION) 86
11 CONJUGATE VACCINE MARKET, BY GEOGRAPHY, 2012 – 2022 ($BILLION) 88
12 SUBUNIT VACCINE MARKET, BY GEOGRAPHY, 2012 – 2022 ($BILLION) 90
13 RECOMBINANT VECTOR VACCINE MARKET, BY GEOGRAPHY, 2012 – 2022 ($BILLION) 92
14 DNA VACCINE MARKET, BY GEOGRAPHY, 2012 – 2022 ($BILLION) 94
15 SYNTHETIC VACCINE MARKET, BY GEOGRAPHY, 2012 – 2022 96
16 DENTRITIC VACCINE MARKET, BY GEOGRAPHY, 2017 – 2022 ($BILLION) 98
17 GLOBAL VACCINE MARKET, BY DISEASE INDICATION, 2012 – 2022 ($BILLION) 100
18 INFECTIOUS DISEASE VACCINE MARKET, BY GEOGRAPHY, 2012 – 2022 ($BILLION) 102
19 CANCER VACCINE MARKET, BY GEOGRAPHY, 2012 – 2022 ($BILLION) 104
20 ALLERGY VACCINE MARKET, BY GEOGRAPHY, 2012 – 2022 ($BILLION) 106
21 OTHERS (CARDIOVASCULAR DISEASE, DIABETES, SMOKE CESSATION) POTENTIAL MARKET,
BY GEOGRAPHY, 2016 – 2022 ($BILLION) 108
22 REVENUE OF TOP 5 COMPANIES 127
List of Figures

Fig -1 GLOBAL VACCINE MARKET, 2007 – 2012 ($BILLION) 27
Fig -2 GLOBAL VACCINE TECHNOLOGIES MARKET, 2012 – 2022 ($BILLION) 29
Fig -3 Porter's Value Chain Analysis 55
Fig -4 GLOBAL VACCINE MARKET, 2007 – 2012 ($BILLION) 58
Fig -5 GLOBAL VACCINE TECHNOLOGIES MARKET, 2013 – 2022 ($BILLION) 58
Fig -6 VACCINE TECHNOLOGIES MARKET, BY GEOGRAPHY, 2012 – 2022 ($BILLION) 59
Fig -7 VACCINE TECHNOLOGIES MARKET SHARE, BY GEOGRAPHY, 2012 – 2022 60
Fig -8 GLOBAL VACCINE TECHNOLOGIES MARKET, BY END-USER, 2012 – 2022 ($BILLION) 69
Fig -9 GLOBAL VACCINE TECHNOLOGIES MARKET SHARE, BY END-USER, 2012 – 2022 70
Fig -10 PAEDRIATIC VACCINE MARKET, BY GEOGRAPHY, 2012 – 2022 71
Fig -11 PAEDRIATIC VACCINE MARKET SHARE, BY GEOGRAPHY, 2012 – 2022 72
Fig -12 ADULT VACCINE MARKET, BY GEOGRAPHY, 2012 – 2022 73
Fig -13 ADULT VACCINE MARKET SHARE, BY GEOGRAPHY, 2012 – 2022 74
Fig -14 GLOBAL VACCINE TECHNOLOGIES MARKET, BY TYPE, 2012 – 2022 75
Fig -15 GLOBAL VACCINE TECHNOLOGIES MARKET SHARE, BY TYPE, 2012 – 2022 76
Fig -16 PREVENTIVE VACCINE MARKET, BY GEOGRAPHY, 2012 – 2022 77
Fig -17 PREVENTIVE VACCINE MARKET SHARE, BY GEOGRAPHY, 2012 – 2022 78
Fig -18 THERAPEUTIC VACCINE MARKET, BY GEOGRAPHY, 2012 – 2022 79
Fig -19 THERAPEUTIC VACCINE MARKET SHARE, BY GEOGRAPHY, 2012 – 2022 80
Fig -20 GLOBAL VACCINE TECHNOLOGIES MARKET, BY TECHNOLOGY CLASS, 2012 – 2022 ($Billion) 82
Fig -21 GLOBAL VACCINE TECHNOLOGIES MARKET SHARE, BY CLASS, 2012 - 2022 83
Fig -22 LIVE/ATTENUATED VACCINE MARKET, BY GEOGRAPHY, 2012 – 2022 84
Fig -23 LIVE/ATTENUATED VACCINE MARKET SHARE, BY GEOGRAPHY, 2012 – 2022 85
Fig -24 TOXOID VACCINE MARKET, BY GEOGRAPHY, 2012 – 2022 86
Fig -25 TOXOID VACCINE MARKET SHARE, BY GEOGRAPHY, 2012 – 2022 87
Fig -26 CONJUGATE VACCINE MARKET, BY GEOGRAPHY, 2012 – 2022 88
Fig -27 CONJUGATE VACCINE MARKET SHARE, BY GEOGRAPHY, 2012 – 2022 89
Fig -28 SUBUNIT VACCINE MARKET, BY GEOGRAPHY, 2012 – 2022 ($BILLION) 90
Fig -29 SUB-UNIT VACCINE MARKET, BY GEOGRAPHY, 2012 – 2022 91
Fig -30 RECOMBINANT VECTOR VACCINE MARKET, BY GEOGRAPHY, 2012-2022 92
Fig -31 RECOMBINANT VECTOR VACCINE MARKET SHARE, BY GEOGRAPHY, 2012 – 2022 93
Fig -32 DNA VACCINE MARKET, BY GEOGRAPHY, 2012 – 2022 ($BILLION) 94
Fig -33 DNA VACCINE MARKET, BY GEOGRAPHY, 2012 – 2022 95
Fig -34 SYNTHETIC VACCINE MARKET, BY GEOGRAPHY, 2012 – 2022 96
Fig -35 SYNTHETIC VACCINE MARKET SHARE, BY GEOGRAPHY, 2012 – 2022 97
Fig -36 DENTRITIC VACCINES, BY GEOGRAPHY, 2012 – 2022 98
Fig -37 DENTRITIC VACCINE MARKET SHARE, BY GEOGRAPHY, 2012 – 2022 99
Fig -38 GLOBAL VACCINE MARKET, BY DISEASE INDICATION, 2012 – 2022 100
Fig -39 GLOBAL VACCINE MARKET SHARE, BY DISEASE INDICATION, 2012 – 2022 101
Fig -40 INFECTIOUS DISEASE VACCINE MARKET, BY GEOGRAPHY, 2012 – 2022 102
Fig -41 INFECTIOUS DISEASE VACCINE MARKET SHARE, BY GEOGRAPHY, 2012 – 2022 103
Fig -42 CANCER VACCINE MARKET, BY GEOGRAPHY, 2012 – 2022 ($BILLION) 104
Fig -43 CANCER VACCINE MARKET, BY GEOGRAPHY, 2012 – 2022 105
Fig -44 ALLERGY VACCINE MARKET, BY GEOGRAPHY, 2012 – 2022 106
Fig -45 ALLERGY VACCINE MARKET SHARE, BY GEOGRAPHY, 2012 – 2022 107
Fig -46 OTHERS (CARDIOVASCULAR DISEASE, DIABETES, SMOKE CESSATION) POTENTIAL MARKET, BY GEOGRAPHY, 2016 – 2022 ($BILLION) 108
Fig -47 OTHERS (CARDIOVASCULAR DISEASE, DIABETES, SMOKE CESSATION) POTENTIAL MARKET, BY GEOGRAPHY, 2016 – 2022 109
Fig -48 GLOBAL VACCINE TECHNOLOGIES MARKET, BY GEOGRAPHY, 2012 – 2022 111
Fig -49 VACCINE- INVESTOR NETWORK 123
Fig -50 GLOBAL VACCINE MARKET SHARE, BY KEY PLAYER, 2013 127
Fig -51 REGULATORY APPROVAL PROCESS 136
Fig -52 TOTAL PATENTS FILED BETWEEN 2008 – 2013 142
Fig -53 PATENT ANALYSIS BY COMPANIES (2008 – 2012) 142